{"doi":"10.1093/oncolo/oyaf208","title":"Dupilumab for bullous pemphigoid related to immune checkpoint inhibitors: a retrospective case series","abstract":"BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but are associated with treatment-limiting immune-related cutaneous adverse events (irCAEs). Immune checkpoint inhibitor-related bullous pemphigoid (irBP), a severe, blistering irCAE occurs in 0.3%-1.5% of patients receiving ICI therapy. While systemic steroids can be effective, they are associated with significant toxicity and may mitigate -immunotherapy antitumor efficacy. Consequently, steroid-sparing therapies are needed. Dupilumab, an IL-4 and IL-13 receptor antagonist, has demonstrated efficacy in non-ICI-related BP and appears promising for managing irBP. METHODS: We conducted a retrospective review of patients treated with dupilumab for irBP from April 2020 to April 2024. Clinical data, outcomes, and adverse events were assessed. Inhibitor-related bullous pemphigoid response was categorized as complete response (CR), partial response (PR), or no response (NR). RESULTS: In all, 17 patients (59% male, 82% non-Hispanic White; mean age 72.7 years) developed irBP while receiving PD-1/PDL-1 inhibitors. Sixteen patients (94%) received dupilumab for active irBP and one (6%) for prevention of recurrence. Dupilumab achieved CR of irBP for 12 patients (75%) and PR for 2 (12%) patients with active irBP. Ten (62%) achieved CR with dupilumab systemic monotherapy. Median time to first response was 19.5 days (range = 3-50). Most patients with CR (58%) failed prior oral corticosteroid therapy. The patient treated prophylactically experienced no irBP recurrence. Dupilumab was well-tolerated, with no adverse events. CONCLUSIONS: Dupilumab is a promising steroid-sparing option for irBP, achieving initial response in under 20 days for most cases. Dupilumab is a valuable tool to manage this challenging irCAE while minimizing risk related to systemic steroid treatment.","journal":"The Oncologist","year":2025,"id":512615,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":12,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9635,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":227790,"name":"Andrea P. Moy","orcid":"0000-0001-5431-6682","position":1,"is_corresponding":false},{"id":347687,"name":"Stephen W. Dusza","orcid":"0000-0002-0747-2479","position":2,"is_corresponding":false},{"id":246211,"name":"Alison J. Moskowitz","orcid":"0000-0002-3408-050X","position":3,"is_corresponding":false},{"id":90739,"name":"Gopa Iyer","orcid":"0000-0002-5093-6099","position":4,"is_corresponding":false},{"id":237145,"name":"Afsheen N. Iqbal","orcid":"0000-0003-4980-9954","position":5,"is_corresponding":false},{"id":226686,"name":"Robert J. Motzer","orcid":"0000-0001-6925-2327","position":6,"is_corresponding":false},{"id":231592,"name":"David H. Ilson","orcid":"0000-0003-0831-2247","position":7,"is_corresponding":false},{"id":256636,"name":"Roisin E. O’Cearbhaill","orcid":"0000-0001-8217-4554","position":8,"is_corresponding":false},{"id":1372171,"name":"Rashek Kazi","orcid":"0000-0002-9243-9007","position":9,"is_corresponding":false},{"id":1023928,"name":"Jennifer DeFazio","orcid":"0000-0003-2431-3370","position":10,"is_corresponding":false},{"id":992463,"name":"Allison Gordon","orcid":"0000-0002-1297-123X","position":11,"is_corresponding":false},{"id":408819,"name":"Alina Markova","orcid":"0000-0002-2427-3199","position":12,"is_corresponding":false},{"id":1372170,"name":"Ian Nykaza","orcid":"0000-0001-9620-8276","position":0,"is_corresponding":true}],"reference_count":33,"raw_metadata":null,"created_at":"2026-07-19T02:48:06.263458Z","pmid":"40638215","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}